Granules India Ltd. has officially closed the acquisition of Senn Chemicals AG, a Switzerland-based CDMO specialising in peptide development and manufacturing. This strategic move marks Granules’ entry into the peptide therapeutics segment and contract development and manufacturing (CDMO) services, bolstering its innovation-led growth strategy. The acquisition, executed through Granules’ wholly owned subsidiary Granules Peptides Pvt. Ltd., involves a 100% equity stake purchase from the founding Senn family. Headquartered in Dielsdorf, Switzerland, Senn Chemicals brings over six decades of expertise in Liquid-Phase and Solid-Phase Peptide Synthesis (LPPS & SPPS), serving pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets. Dr. Krishna Prasad Chigurupati, Chairman and MD of Granules India, highlighted the deal as a “pivotal step” in the company’s evolution into a science- and innovation-led enterprise. He emphasised the synergy between Senn’s peptide specialisation and Granules’ global manufacturing capabilities to drive high-quality, next-gen treatments in areas such as GLP-1 receptor agonists, anti-diabetic, and anti-obesity therapies. The acquisition also marks Granules’ formal entry into the CDMO sector, enhancing its global footprint with access to regulated markets, top-tier European scientific talent, and advanced R&D capabilities. Joint development initiatives in peptide APIs are already underway, with an expanded pipeline in the works. Advisors on the deal included Stifel Nicolaus India (financial), Loyens & Loeff (legal), Deloitte (financial and tax diligence), and Kroll (valuation). This acquisition strengthens Granules’ innovation capabilities and positions it as a key player in the rapidly growing complex therapeutics and CDMO markets. (BSE)